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INTRODUCTION
   
           Varicella Zoster virus (VZV) belongs to Herpesviridae family 
(Sub family: Alpha herpesviridae ).
           Herpes viruses measure approximately 200 nm in diameter and contain linear, double 
stranded  DNA  core  enclosed  within  a  protein  capsid,  covered  by  a  tegument  and 
glycoprotein containing envelope. Biological properties unique to herpes viruses include 
latency and reactivation.    
           Varicella zoster (Chicken Pox) and Herpes zoster (Shingles) are caused by same  
varicella zoster virus. 
 Herpes zoster is  a  localized disease characterised by multiple superficial  painful 
grouped  vesicles  on  an  erythematous  base  involving  a  particular  dermatome  due  to 
reactivation of varicella zoster virus that is lying dormant in sensory ganglion.   
 Most  often Varicella  is  a  self-limited infection of  childhood.  Zoster  is  mainly a 
disease of adults. A prerequisite for developing zoster is a prior episode of varicella, which 
on occasion may have been sub-clinical.
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During Varicella infection, Varicella zoster virus remains latent inside the sensory 
nerve  ganglion.  Zoster  results  when  the  latent  virus  reactivates  and  returns  from  the 
ganglion to infect the skin.
Most  often  Varicella  zoster  virus  reactivation  occurs  in  the  setting  of  relative 
immunological  compromise,  such  as  aging,  local  trauma  immunosuppression  (Steroids,  
HIV), frontal sinusitis, radiation and tumor involvement of spinal cord. 
REVIEW OF LITERATURE
History
          The  term ‘HERPES’ has  been  used  in  medicine  since  from 
Hippocrates and is derived from Greek word “Erpein” meaning “to creep” 
The term “Zoster” also a Greek word meaning “Girdle” ascribes   the rash 
has belt like appearance. The other commonly used synonym “Shingles” is 
derived from the Latin word cingulum or singlullus. One more synonym for 
zoster is “Zona”. The Norwegians call zoster as “belt of roses from hell” and 
Danes calls it “hell fire” a very apt.
         The relationship of zoster to varicella was first noted by Hungarian 
pediatrician VonBokay (1888). After that Kondrafitz (1925) and Brunsgaard 
confirmed that  same agent  was  responsible  for  both  varicella  and zoster 
(1932) Seiler (1949) and Hope Simpson (1954) also reported epidemiologic 
evidence  that  zoster  and  varicella  were  caused  by  same  virus.  Later 
Lipschutz 1921 reported that zoster lesions were identical histologically to 
that  of  varicella  as previously described by Tyzzer.  Zoster  occurs due to 
reactivation of latent virus .This was first suggested by Garland (1943) and 
later Hope-Simpson (1965) reasoned that it is due to reactivation of latent 
virus occurring since the primary infection. 
Epidemiology
         Incidence 3.4 cases per 1000(Hope –Simpson and Ragozzino etal 
1945-1959), No racial or seasonal prediction. Both sexes equally affected. 
Incidence increases with age. 2/3 cases occur in individuals over 50 years of  
age.  Less than 10% of cases occur below the age of 20 years, Life time 
incidence of HZ was observed to be 10-20% in general population and an 
annual incidence of 600,000 to 850,000 cases of HZ have been reported in 
U.S.   Spread –Direct contact, Aerosol. 
Virology of zoster
HZ is caused by varicella –Zoster virus (VZV), same virus causing 
Varicella.  Previously  called  as  herpes  virus  varicella.It  is  a  DNA virus 
belonging  to  subfamily  of  herpes  viridae  family  and  also  designated  as 
Human herpes virus 3.
Structure
Electron microscopically varicella zoster virus is a typical herpes like 
particle, 150-200 nm in diameter, with a lipid envelope bearing glycoprotein 
spikes  (peplomers).  The  central  region  of  virus  contains  an  icosahedral 
nucleocapsid composed of 162 capsomere within which is the viral genome. 
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Between the nucleocapsid and the envelope is an amorphous, protein filled 
space  known as  tegument  .Five  families  of  viral  glycoprotein have been 
identified,  gpI,gpII,gpIII,gpIV,gpV and  they  are  the  primary  markers  for 
both humoral and cell mediated  immunity.
Pathogenesis
Herpes zoster is the result of reactivation of endogenous virus that 
had  persisted  in  latent  form within  sensory  ganglia  following  an  earlier 
attack of varicella.
Latency
 Varicella zoster viral DNA is localized primarily in trigeminal and 
thoracic  ganglion  ,  corresponding  to  dermatomes  in  which  chicken  pox 
lesions  are  maximal  and  which  are  most  commonly  involved  by  zoster 
presumably  because  areas  of  skin  with  a  dense  rash  during.varicella 
transmits larger amounts of virus to corresponding sensory ganglia and thus 
establishing  latency  in  large  number  of  ganglionic  cells.  Subsequently 
reactivation occurs at random and it is in these maximally infected ganglia 
with  their  corresponding  innervated  skin  manifest  the  lesions  more 
frequently.  Two concepts  prevail  about  the  establishment  of infection  in 
ganglia.
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One during the  course  of  varicella,  vzv passes  from lesions  in  skin  and 
mucus  membranes  into  contiguous  sensory  nerve  endings,  and  then  to 
sensory ganglia or alternatively, varicella zoster virus might also reach the 
ganglia  via  the  blood stream during the  course  of  primary or  secondary 
viremia of varicella.
Reactivation
    The level of antibody is considered to be the critical determinant of 
host’s  capacity  to  contain  VZV reversion.  Based  on  number  of  studies 
conducted at various places, it now appears that cellular immunity (CMI) is 
more important, principally that of T lymphocytes in host resistance to this 
recurrent VZV infection of endogenous origin.
 The  mechanisms  involved  in  the  activation  are  unknown  .Most 
patients are otherwise healthy without any predisposing factors. Conditions 
associated with increased occurrence include immunosuppression in  HIV 
infection and Hodgkin’s disease and other malignancies like lymphocyte and 
granulocytic  leukemia  or  other  malignancies,  administrations  of 
immunosuppressive  drugs  and   corticoids,  irradiation  of  spinal  column 
tumor involvement of cord, dorsal root and adjacent structures, local trauma, 
surgical manipulations of spine, heavy metal poisoning and therapy (arsenic) 
and frontal sinusitis for precipitant of ophthalmic zoster in 16% cases. Virus 
multiplies and spread with in the ganglion, causing neuronal necrosis and 
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intense inflammation. The VZV spreads antidromically down the sensory 
nerve with in   the axon sheath and is released around sensory nerve endings 
in  skin,  where  multiplication  of  virus  within  the  epidermal  cells  causes 
swelling, and vesicle formation due to edema, spread of ganglionic infection 
proximally along the posterior nerve root to meninges and cord results in 
local  leptomeningitis,  cerebrospinal  fluid  pleocytosis  and  segmental 
myelitis.
Infection  of  motor  neurons  in  anterior  horn  and  inflammation  of 
anterior  nerve  root  account  for  local  palsies  that  may  accompany  the 
cutaneous  eruption  and extension of  infection within the central  nervous 
system  may  result  in  rare  complications  of  herpes  zoster  such  as 
meningoencephalitis and transverse myelitis.
Pathology
Cutaneous lesions
Early stage
An early papular  lesion,  the epithelium is  slightly  elevated due to 
swelling of infected epithelial cells and to edema and vascular congestion of 
underlying dermis. In the superficial dermis, capillary endothelial cells are 
swollen, and they often contain typical intranuclear inclusion bodies. Similar 
inclusion  bodies  may  be  seen  in  nuclei  of  fibroblast  in  the  surrounding 
connective tissue, which is edematous and infiltrated by small number of 
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mononuclear cells. Superficial lymphatics are dilated and cells lining these 
structures are also swollen and may contain intranuclear inclusion bodies, 
cells  of  germinal  layer  and  the  deeper  portion  of  stratum spinosum are 
involved  initially  and  show  ballooning  degeneration  due  to  viral 
multiplication with loss of intracellular bridges and are soon separated by 
intercellular edema (Secondary acantholysis).Only few small multinucleated 
giant cells possessing 3-8 nucleus are seen at this stage. The epithelium is  
only slightly elevated.
Vesicular stage
           As a  result of infection and degeneration of increasing number of cells, 
fusion of  adjacent  areas  of  degeneration  and continuing influx  of  edema 
fluid (reticular degeneration), the  papule transform into a vesicle, the roof 
being formed by upper malphigian and horny layers. The cellular vesicle 
fluid  contains fibrin, ballooned epithelial cells, and abundant cell free viral  
particles,  Multinucleated  giant  cells  contain  upto  15  nuclei  which  are 
nothing  but  fused  epithelial  cells  containing  eosinophilic  intranuclear 
inclusion bodies (Lipschutzbodies formely cowdry typeA bodies) of 3-8 nm 
diameter.  The  upper  dermis  beneath  the  vesicle  contain  inflammatory 
infiltrate,  mainly  of  lymphocytes,  monocytes  and  some  eosinophils  and 
neutrophils.
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Late Stage
           Invasion of polymorphonuclear leucocytes and a small number of 
macrophages from underlying dermis, invade the vesicles transforming them 
into  pustules.  The  fluid  is  then  absorbed,  with  the  formation  of  a  flat  
adherent crust that is eventually detached by regrowth of subjacent epithelial 
cells. The evolution from papule to early crusting normally occurs over a 
period  of  24-  48  hrs.  Lesions  of  uncomplicated  varicella  heal  with  out 
scarring.
Mucous membrane lesion
          Lesion in mucous membranes develop in the same way as cutaneous 
lesion but the roof of the vesicle rupture quickly to produce a shallow ulcer 
that heals rapidly.
Clinical features
Prodrome of Herpes zoster
        Initial Symptoms are usually pain and paresthesia in the involved 
dermatome, preceding  the eruption by 1-4 days ,and varies from superficial  
itching ,tingling or burning to severe, deep boring or lancinating   pain .It 
may  be  constant  or  intermittent  and  is  accompanied  by  tenderness  and 
hyperesthesia of involved dermatome which is a useful predictive sign for 
diagnosis .The pre-eruptive pain may stimulate migraine headache, pleurisy, 
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myocardial  infarction,  duodenal  ulcer,cholecystitis,  biliary  or  renal  colic, 
appendicitis,  prolapsed  intervertebral  disc  or  early  glaucoma  depending 
upon the level of involvement which may lead to serious misdiagnosis.
        Constitutional symptoms including headache, fever occur in about 5% 
pts,  usually  in  children  and  may  proceeded  the  rash  by  1-2  days  and 
gradually  subside  as  the  eruption  appears.  A  tender,  regional 
lymphadenopathy is present in most of cases at this stage.
        Some patients experience acute segmental neuralgia without being 
followed by a cutaneous eruption called as “Zoster sine eruptione”.Zoster 
sine eruption, presumably reflecting an aborted eruption, and the concurrent 
rise in antibodies to VZV provides evidence that it is due to herpes zoster. A 
few other patients may never experience skin lesions but have pain or visual 
or  ocular  lesions  which may be  severe.  Although facial  palsy frequently 
complicates (Ramsay-Hunt syndrome) VZV infection does not appear to be 
responsible for most cases of idiopathic facial palsy (Bell’s palsy)
Eruptive phase
        The most distinctive feature of Zoster is localization of rash, which is 
nearly always unilateral does not cross the midline and is generally limited 
to the area of skin innervated by a single sensory ganglion, though one or 2 
adjacent dermatomes may be involved. Occasionally, a few vesicles appear 
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to cross the midline on the opposite side, owing to transverse nerve twigs. 
Eruption is rare in bilaterally symmetric or asymmetric dermatomes .Herpes 
Zoster tend to in volute more slowly and usually consist of closely grouped 
vesicle on an erythematous base, rather than the more discrete, randomly 
distributed vesicles of varicella .The lesion begin as erythematous macules 
and  papules  which  often  first  appear  where  superficial  branches  of  the 
affected sensory nerve are given off. 
E.g.  Posterior  primary  division  and  the  lateral  and  anterior  branches  of 
anterior primary division of spinal nerve .Vesicles form within 12-24 hrs in 
clusters from the erythematous and the edematous base (i.e, inflammatory 
base) and evolve into pustules by day 3 or 4 successive crops continue to 
appear  for  up  to  7  days,  usually  1-4  days.  Vesicles  either  umblicate  or 
rupture before forming a crust in 7-10 days which generally fall off in 2 to 3  
weeks  in  normal  individuals.  Patient  is  considered  to  be  contagious  for 
about 7 days after the appearance of rash till the crusting stage.    The rash is 
most  severe  and  lasts  longer  in  older  people  and  is  least  severe  and  of 
shorter duration in children. Pain generally remits as the crusts fall off but 
may persist for longer even after the healing of rash and may intensify later. 
Segmental pain, prominent feature of Zoster in older person and it is seldom 
a significant symptom in children.
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       Herpes Zoster occurs with greatest frequency in those areas in which 
the rash of varicella was most abundant. The trunk from T3 to L2  division 
and ophthalmic division of trigeminal nerve most frequently affected and 
rarly lesions occur below the knee and elbow. But in infants and children, 
localization to cervical with lumbosacral region is characteristic. 
In  order  of  frequency  it  has  been  reported,  in  adult  to  affect  thoracic 
dermatome in 50-55%, cranial  nerves 15-20%, cervical  dermatome 14%, 
lumbar 14% and sacral 2%
        The elderly or debilitated patients may have prolonged and difficult  
course. For them, the eruption is typically more extensive and inflammatory. 
Occasionally  resulting  in  hemorrhagic  blisters,  skin  necrosis,  secondary 
bacterial infection or extensive scarring, which is sometimes hypertrophic or 
keloidal.
Clinical types of herpes zoster
      Thoracic zoster
      Cervical zoster
      Trigeminal zoster
      Lumbosacreal zoster
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Clinical zoster variations
      Disseminated herpes zoster 
      Herpes zoster with aberrant vesicles 
      Herpes zoster at two different sites
      Zoster sine herpete
      Bilateral zoster
     Recurrent zoster
     Zoster Ophthalmicus 
     Zoster oticus or Ramsay hunt syndrome
     Glosssopharyngeal & Vagal zoster
     Sacral Zoster 
     Zoster encephalomyelitis
     Zoster Hemiplegia syndrome 
     Dermatological dyspnoea –Diaphragm
      Phantom hernia
1. Trigeminal nerve zoster
       The fifth cranial nerve or trigeminal nerve has 3 main divisions, namely 
ophthalmic,  maxillary  and  mandibular.  The  ophthalmic  division  further 
divides into three main branches ,namely frontal,lacrimal  and nasociliary 
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nerves.  Frontal  nerves  in  turn  divides  into  supraorbital  and 
supratrochlearnerves.  Involvement  of  any  branch  of  ophthalmic  nerve  is 
called “Herpes zoster ophthalmicus”
a. Herpes zoster ophthalmicus
       10-15 % cases of Herpes Zoster involve the ophthalmic division of 
trigeminal nerve. The rash of ophthalmic zoster may extend from level of 
eye to the vertex of skull,  but it  does not cross the midline of forehead. 
Nasociliary  branch  supplies  the  tip  and  sides  of  nose  and  intra  ocular 
structures. Nasociliary involvement which occurs in 30-40% of ophthalmic 
nerve  involvement,  vesicle  on tip  and side of  nose  (Hutchison’s  sign)  is 
associated with most  serious  ocular  complication including conjunctivitis 
commonly  and  rarly  keratitis,  scleritis,  uveitis  extra  ocular  palsies  very 
rarely. 
       Frontal  sinusitis  preceded 16% of all  cases  of ophthalmic Herpes 
Zoster. Patients with ophthalmic herpes zoster who are HIV negative tend to 
have less severe infection and also recover faster than those, who are HIV 
positive. Herpes Zoster ophthalmicus is a known marker of HIV/AIDS in 
Africa.
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b. Herpes zoster of Maxillary division of trigeminal nerve.
       Zoster of maxillary divisions of trigeminal nerve produces vesicles on 
palate, uvula and tonsillar area.
c. Herpes Zoster of mandibular division of trigeminal nerve. 
       Zoster of mandibular divisions of trigeminal nerve produces vesicles on 
anterior  part  of  tongue,  floor  of  mouth  and  buccal  mucosa.In  oro-facial 
zoster, tooth aches may be the presenting symptoms since alveolar braches 
of this division supply the periodontal structures.
2. Facial nerve
       Involvement of geniculate ganglion leads to a triad of facial palsy in  
combination  with  herpes  zoster  of  external  ear  or  tympanic  membrane 
(Herpes zoster oticus) with or without tinnitus, vertigo and deafness (in 37% 
patients)  the  so  called  “Ramsay  Hunt  syndrome”  This  results  from 
compression of facial and auditory nerves probably caused by swelling of 
sensory fibres, while passing through the confined spaces of facial canal of 
internal auditory meatus. Involvement of special sensory fibres may lead to 
painful vesicles on uvula, palate and anterior part of tongue, associated with 
loss  of  taste  sensation  over  the  anterior  two  third  of  ipsilateral  side  of 
tongue. Sensory fibres from facial nerve innervate deep facial tissues, hence 
jaw pain stimulating a dental abscess is often present.
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3. Glossopharyngeal (ix) and vagal(x) nerve
       Glossopharyngeal Zoster produces pain in ear and pharynx and vesicles 
and ulcer on soft palate and ear. Vagal zoster may produce vesicles on base 
of tongue, epiglottis and arytenoids and may cause paresis of larynx and 
pharynx as well as cardiac and epigastric distress.
Cervical zoster  
       Zoster of upper cervical roots (C2,C3,C4) produce lesions on the scalp, 
neck retro auricular region known as “Herpes occipitocollaris” and this may 
be associated with “Ramsay Hunt syndrome” (can also involvement of IX,X 
cranial nerves). With lesions of cervical nerve II (also cranial nerve V) in 
scalp, alopecia may rarely occur and may lead to scarring lower cervical 
roots involvement affects the upper limbs. 
Thoracic zoster 
       Thoracic dermatomes are most frequently affected (55%) than the other 
dermatomes .The rashes are nearly always unilateral localized and do not 
cross the midline, and is generally limited to the area of skin innervated by a  
single  sensory  ganglion.  Pain  in  the  thoracic  dermatome  leads  to  a 
misdiagnosis of peptic ulcer disease, gall bladder diseases, renal colic and 
myocardial  infarction.  Abdominal  hernia  occurs  especially  in  zoster 
involving the thoracic dermatome T10 - T11.Electrocardiographic changes 
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sometimes may be noted with left upper thoracic zoster and galactorrhea in 
females has been reported with zoster involving   the mammary areas.
Sacral zoster (s2,s3.s4)
      Cutaneous lesions are limited to a narrow segment on posterior aspect of 
calf and thigh for S2 dermatome and perianal region of gluteal skin for other  
roots.  Sacral  zoster  is  mainly  associated  with  bladder  and/or  bowel 
dysfunction due to migration of virus to adjacent autonomic nerves, leading 
to urinary hesitancy or urinary retention.
Bilateral herpes zoster
        Herpes Zoster is almost always unilateral. The rarity of bilateral cases is 
indicated by individual case reports in the literature.
Herpes zoster with multiple unilateral lesions
        This type is quite rare and most likely to be noted in persons with some 
severe systemic  illness  i.e.  Hodgkin’s  lymphoma, metastatic  cancer,  HIV 
etc.  such  disease  should  be  looked  for  when  this  dermal  distribution  is 
encountered.
Recurrent herpes zoster 
       Recurrent attacks are rare and zoseriform herpes simplex should always 
be noted out.
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Zoster in malignancy
         Herpes zoster has been reported with Hodgkin’slymphomas, leukemias, 
metastatic  cancer  and  other  neoplasm.  The  presence  of  Herpes  Zoster 
especially  in  an  older  person  indicates  the  need  for  searching  for  these 
diseases as a causative background. Use of cytotoxic immunosuppressant 
therapy altering immune response may also be a factor.
Herpes zoster in HIV infection
         Herpes zoster is included in clinical stage -II of WHO staging system 
for HIV infection.  
         Herpes Zoster occurring in HIV disease is usually typical in involving  
one  or  two  adjacent  dermatomes  but  uncommonly  it  may  be 
multidermatomal,  recurrent  within  the  same  dermatome  or  disseminated. 
The  eruption  may  be  bullous,  hemorrhagic,  necrotic  and  may  be 
accompanied by severe pain.
         The majority of HIV infected patients with herpes zoster experience an  
uneventful recovery, however atypical clinical course of herpes zoster is not 
uncommon.  Lesions  may  persist  for  months,  either  in  localized  or 
disseminated form, appearing as hyperkeratotic, ulcerating, painful nodules, 
often with central crusting or ulceration with a border of vesicles.
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Systemic  dissemination  of  herpes  zoster  with  hepatitis,  encephalitis  and 
pneumonitis  is  common. HIV infected patients  with herpes  zoster  show 
increased  neurological  and  ophthalmic  complications  particularly  retinal 
necrosis. Reactivation of varicella zoster virus is the commonest cutaneous 
manifestation of immune restoration disease.
Herpes zoster in children
         Herpes zoster in neonates and children may represent the result of an  
attenuated response to intrauterine or neonatal infection. Baba et al reported 
that children who had varicella before 2 months of age has lower Varicella 
zoster antibody titres and diminished skin test reactions, thus reactivation in 
these cases may be secondary to an abnormal immune response to primary 
infection by Varicella.
         The development of herpes zoster is often preceded by radicular pain 
and is less common in children. Malaise, headache and fever may precede 
the rash, particularly in younger patients. Resolution of lesion occurs within 
1-3 week.
         Both normal and immunosuppressed patients may have generalization 
of  herpes  zoster.  Post  herpetic  neuralgia  is  uncommon  in  children. 
Immunocompromised children with herpes zoster may have more extensive 
involvement with a higher risk of viremia and visceral dissemination.
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Herpes zoster in pregnancy 
         Herpes Zoster during pregnancy whether it occurs early or late in 
pregnancy appears to have no deleterious effects on either the mother or 
infant.  Maternal  zoster  in  pregnancy  is  not  associated  with  intrauterine 
infection  .But  maternal  varicella  in  the  first  20  weeks  of  pregnancy  is 
associated with a approximate 2% risk of fetal damage.
Complications
A. Acute complications of herpes Zoster
        Acute complications occur during the course of illness and are more 
common in immunocompromised individuals.
i. Cutaneous complications 
       The  common  cutaneous  complications  are  secondary  bacterial 
infections,  cutaneous necrosis,  scarring, and dissemination and gangrene 
formation.
ii. Ocular complications       
      Ocular  complications  include  uveitis,  keratitis,  conjunctivitis, 
conjuctival  edema,  ocular  muscle  palsies,  proptosis,  sclerosis,  retinal 
vascular  occlusion  and  ulceration  scarring  and  even  necrosis  of  lid. 
Involvement of ciliary ganglion may give rise to Argyl-Robertson pupil.
 
19
         Acute retinal necrosis caused by varicella zoster virus occasionally 
occurs in immuno competent patients, although more recent studies have 
focused on ocular disease in HIV infected patient.
iii. Neurological complications
        This includes cranial neuritis, motor neuropathy, autonomic 
neuropathy, aseptic meningitis, meningo-encephalitis, transverse myelitis, 
necrotizingmyelopathy, Guillain-barresyndrome, hemiplegia and 
granulomatous angitis.
 a. cranial neuritis 
        Cranial  neuritis  includes Trigeminal nerve zoster (Herpes zoster 
ophthalmicus,  maxillary  and  mandibular,  nerve  zoster),  Ramsay-Hunt 
syndrome with involvement of facial nerve and 8th cranial nerve, Vagus 
and Glosso pharyngeal nerve zoster.
 b. Motor neuropathy
      This occurs in 5% cases and is more common in older patients and 
those with malignancy and in cranial when compared with spinal nerve 
involvement  .The  motor  weakness  usually  follows  the  pain  and  the 
eruption  by a  few days  to  a  few weeks  ,but  occasionally  precedes  or 
accompanies them. The affected segment is usually but not always the 
same.  Complete  recovery  is  expected  in  55  %  and  significant 
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improvement  in  a  further  30%  of  cases  .In  ophthalmic  zoster  ocular 
palsies  occur  in  13%  and  facial  palsies  in  7%.An  abdominal  hernia 
followed zoster involving thoracic 10th and 11th motor roots.  Zoster of 
anogenitial  area  may  be  associated  with  disturbances  of  defecation  or 
urination  Herpes  zoster  oticus  accounts  for  about  10% of  cases  facial 
palsy  .Glossopharyngeal  and  vagal  zoster  produces  pharyngeal  with 
palatal muscle weakness. Zoster of 2nd to 4th cervical nerve may paralyse 
the ipsilateral diaphragm due to involvement of phrenic nerve.
  c. Autonomic neuropathy
      Autonomic nerves system may also be affected. Autonomic nerve 
involvement  often   present  as  bladder  dysfunction  .Gastrointestinal 
involvement present as spasm hypotonia or ileus.
d. Herpes Zoster Meningo encephalitis 
      Neurological symptoms characteristically appear within the first 2 
weeks of onset of skin lesions. Patients at risk are those with trigeminal 
and  disseminated  zoster  as  well  as  the  immunosuppressed.  Rarely 
manifestations of a meningoencephalitis may be significant and at times 
severe enough to cause death.
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e.Granulomatous angitis (or) Delayed contralateral hemiparesis
      By direct  extension along the intracranial  branches of  trigeminal 
nerve, VZV gains access to the CNS infects the cerebral arteries. Patients 
presents with headache and hemiplegia.
 f. Herpes Zoster myelitis
       More rarely, the myelitis lesion predominates in zoster or is the sole 
feature, so that the clinical picture is one of acute onset of paraplegia from 
a diffuse involvement of spinal cord. The picture is that associated with 
acute, transverse myelopathy.  
IV. Visceral complications
       Patients  with  lympho-prolifearative  malignancies  are  at  risk  for 
cutaneous  dissemination  and  visceral  involvement  including  varicella 
pneumontits, hepatitis and meningo encephalitis.
 B. Complications occurring after resolution of herpes zoster lesion
     The commonest and most intractable sequel of zoster is post herpetic 
neuralgia, generally defined as persistence or recurrence of pain for more 
than  a  month  after  the  onset  of  zoster,  but  better  considered  after  3 
months. It occurs in about 30% of patients over 40 years of age and is 
most frequent when trigeminal nerve is involved. 
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     The  pain  has  two  main  forms.  A continuous  burning  pain  with 
hyperesthesia and spasmodic shooting type, although a pruritic ‘crawling 
paraesthesia  may occur.  Allodynia,  pain caused by normally innocuous 
stimuli,  is  often  the  most  distressing  symptom and  occurs  in  90% of 
people with post herpetic neuralgia 
Patho-physiology of pain
      A Number of different overlapping mechanisms appear to be involved 
in the pathogenesis of pain in herpes zoster and post herpetic neuralgia.
      Injury to the peripheral nerves and to neurons in the ganglion triggers 
afferent pain signals. Inflammation in the skin triggers nociceptive signals 
that further amplify cutaneous pain. The abundant release of excitatory 
amino  acids  and  neuropeptides  induced  by  the  sustained  barrage  of 
afferent impulses during the prodrome and acute phase of herpes zoster 
may  caused  excito-toxic  injury  and  loss  of  inhibitory  interneurones  in 
spinal dorsal horn
2. Post –Herpetic itch
      Many  patients  with  shingles  experience  neuropathic  itch 
accompanying pain or itch may be present instead of pain.
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3. Progressive multifocal leuko-encephalopathy 
      In addition to latent infection VZV can produce prolonged smoldering 
sub clinical infection in patients lacking normal defenses to eliminate the 
viral infected cells and resulting in cell-cell spread of infection.
4. Scarring
      Elderly malnourished, debilitated or immunosuppressed patients tent 
to  have a  more  virulent  and extensive  course  of  disease  and scarring. 
Types of scarring seen in zoster are 
• Atrophic
• Hypertrophic
• Keloidal
• Vitiligenous 
• Pitted pigmented (anaesthesia dolorosa)
5. Inflammatory skin lesions following a zoster infection
      (Isotopic response) 
      Following zoster, inflammatory skin lesion may rarely occur  with in 
the  affected  dermatome.  Lesions  usually  appear  with  in  a  month  and 
rarely, longer than 3 month after zoster.
      Lesions reported in herpes zoster scar include a keloid, comedones, 
lichenplanus, giantcelllichenoid dermatitis, urticaria, anulomatous 
vasculitis, granulomatous folliculitis, sarcoidosis, LSA, Morphea, 
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eosinophilic dermatosis, fungal infections, Pseudo lymphoma, lymphoma, 
leukemia cutis, Rosai Dorfman disease, Kaposi’s sarcoma, various skin 
cancers and metastasis.
Diagnosis of herpeszoster 
i. Clinical diagnosis
         Most of the cases, zoster is diagnosed by its clinical features.
ii. Laboratory diagnosis
     1. Morphological test
         Tzanck smear
        Initial test of choice is a cytological smear (Tzanck smear). Test 
does not differentiate herpes simplex from zoster. The base of an early 
lesion is scraped and stained with Hematoxylin eosin (H&E),Leishmans, 
Giemsa,  wrights,  toludineblue  ,Paponicolou  ,or  paragonmultiple  stain. 
The  presence  of  multi  nucleated  giant  epithelial  cells  and  ballooning 
cells  containing intranuclear  acidophilic  inclusion bodies  distinguishes 
the  cutaneous  lesions  produced  by  VZV  from  all  other  vesicular 
eruptions except those produced by herpes simplex virus. Overall it is 
positive in 80% of clinically suggestive lesions and positively high with 
vesicles  and  low  with  pustules  and  with  crusts.  Experience  of  the 
examiner is also important in interpretation.
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2. Skin Biopsy
          Biopsy facilitates reliable diagnosis even in the prevesicular stage and 
provides  more  material  for  histological  examinations,  and  it  is  easier  to 
interpret than Tzanck Smear and of greatest value when gross morphology is 
not  diagnostic  or  characteristic,  as  in  atypical  lesions  such  as  the  chronic 
verrucous lesion produced by   acyclovir resistant vzv in patients with AIDS. 
Biopsy can be done by shave, punch or wedge excision technique. Ballooning 
degeneration  is  peculiar  to  viral  vesicles,  ballooning 
degeneration is found mainly at the base of vesicle, reticular degeneration is 
seen  on  its  superficial  aspect  and  margin.  The  upper  dermis  shows 
inflammatory  infiltrate  composed  of    lymphocytes,  monocytes  and  few 
eosinophils. 
3. Virological Investigations 
a. Viral culture 
     The most definitive test is a positive viral culture from vesicular fluid, 
but  a  minimum  of  48-72  hrs  required  to  produce  the  diagnostic 
cytopathic effects. Infective material is inoculated into human amnion, 
human fibroblast, HeLa or verocells .
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B. Varicella zoster virus antigen detection
      VZV antigen may be demonstrated by immunofluorescence, using a 
commercially available monoclonal antibody to VZV that is conjugated 
to fluorescein.
c. Electron Microscopy
      The ultrastructral features of varicella zoster virus are similar to those 
of  Herpes  simplex  virus.  However  colloidal  gold  immuno  electron 
microscopy  using  monoclonal  antibodies  can  distinguish  between  the 
two conditions.
4. Serological test 
      A number of sensitive serological tests are available to measures 
antibodies to VZV 
 Serological tests include
      1. Fluorescent antibody to membrane antigen (FAMA)
      2. Latex agglutination test.
      3. Enzyme linked immunosorbent Assay (ELISA)
      4. Enzyme Immuno Assay (EIA)
      5. Immune adherence hemagglutination assay (IAHA)
      6. Radio Immuno Assay (RIA)
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      7. Complement fixation test (CFT)
      8. Varicella Zoster virus neutralization tests.
5. Newer Techniques
    1. Nucleic acid probe
           The Nucleic acid hybridization test has also been described for the 
detection of Varicella zoster virus DNA sequences in clinical specimens. The 
Spot hybridization assay used was comparable to cell culture in sensitivity 
and specificity.     
  2 .Polymerase Chain Reaction
          PCR is more sensitive than viral culture or Tzanck smear for detecting 
VZV infections.  PCR was  described  as  particularly  useful  for  rapid  and 
specific  diagnosis  of  VZV infection  without  the  practical  and  technical 
limitations of conventional viral isolations or Tzanck smears.
Treatment
          The aim of treatment is the suppression of inflammation, pain and 
infection.
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General
Non Specific Topical Therapy
         Topical cool compresses, calamine Lotions, Burrow’s solution, Corn 
starch  baking  Soda,  1%  gentian  violet  paint  can  be  used.  Occlusive 
ointments  and  steroid  containing  lotions  and  cream  should  be  avoided. 
Topical antibiotic ointments can also be used in case of secondary infection 
(eg.1% Silver sulphadiazine, soframycin, mupirocin etc.)
Specific
1. Specific Topical therapy
        Idoxuridine in dimethyl sulphoxide,5% acyclovir ointment,1% topical  
trifluoro- thymidine, topical preparation of acyclovir ointment or solution 
effective  in  keratouveitis  in  ophthalmic  zoster,  but  topical  therapy  of 
antiviral agent are not effective in HZ rash.
2. Antibiotics
       Are useful for secondary bacterial infections.
Antiviral therapy
1. ACYCLOVIR
Synthetic purine nucleoside, Deoxy guanosine analogue, 
Specific against herpes viruses, Very active against HSV and VZV  
Less active against CMV and EBV.
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Mechanism of action
        Acyclovir
                Herpes virus specific thymidine kinase
      Acyclovir monophosphate 
                        Cellular kinase
       Acyclovir triphosphate
          ________________________________ 
Inhibits herpes virus DNA 
Polymerase  Competitively                       Gets incorporated 
                                                                     in viral DNA and stops
                                                                     lengthening of DNA
                                                                    strand.Terminated DNA 
                                                                     inhibits DNA polymerase
                                                                     Irreversibly 
        Oral acyclovir significantly reduced the healing time, duration of viral 
shedding and acute pain in randomized controlled trials  in patients  older 
than 50 years of age who were treated within 72 hours of rash onset. 
Oral dose: 800 mg 5 times a day for 7 days. 
Children: 20 mg /kg /Bwt ,   Maximum tolerated dose: 40mg/kg/Bwt   
 IV dose: 10 mg / kg Q8H for 7 days.
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Indications
1. Immunocompetent persons with age 50 years or above
2. Ophthalmic Zoster
3. Localised zoster 
4. Disseminated Zoster
5. Chronic severe zoster in AIDS patients.
6. Ramsay Hunt syndrome.
7. Visceral complications 
2. FAMCYCLOVIR 
        Famciclovir  is  an ester  prodrug of  guanine nucleoside  analogue 
penciclovir. It is converted in the intestine and liver to pencyclovir.
        Penciclovir is phosphorylated to penciclovir triphosphate which in turn 
inhibits viral DNA polymerases and also inhibits extension of nascent viral  
DNA chain.  
Dose: 500 mg TDS for 7 days
3.VALACYCLOVIR
       It  is  the  L-valine  ester  of  acyclovir.  It  was  developed to provide 
increased  oral  bioavailability  of  acyclovir.  Valacyclovir  may  be  more 
effective in resolution of zoster associated pain.
  Dose: 1 gm TDS for 7 days.
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4. FOSCARNET (TRI SODIUM PHOSPHONOFORMATE)
       It is a pyrophosphate containing compound that is active in vitro against 
Varicella zoster virus.
       Foscarnet  noncompetitively inhibit  viral  DNA polymerases  at  the 
pyrophosphate binding sites
       Dose: 40 mg /kg IV Q8Hrly for 14 -21 days.
        Followed by a maintenance does of 120 mg /kg /day.
5. CIDOFOVIR
      It is a phosphonate nucleotide analogue. It has activity against a 
broad  range  of  herpes  viruses.  Cidofovir  does  not  require  initial 
phosphorilation by virus induced kinases, but is converted by host cell 
enzymes to  cidofovir  diphosphate  which is  a  competitive  inhibitor  of 
viral  DNA  polymerases  and  to  a  lesser  extent  to  host  cell  DNA 
polymerase,
6. VIDARABINE (ADENINE ARABINOSIDE)
      It is an adenosine analogue which is phosphorylated intracellular by 
host enzyme and rapidly metabolished to hypoxanthine arabinoside by 
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adenosine  deaminae,  resulting  in  markedly  reduced  antiviral  activity 
within the cells. This instability and systemic toxicity have limited its 
use.
 Dose: 10 mg /  day infused over 12 hrs for 5 days.
7. IDOXURUDINE
       This  synthetic  nucleoside  is  effective  against  DNA viruses, 
particularly  the  herpes  group.  Its  use  is  now  restricted  to  topical 
application because of severe bone marrow and hepatic toxicity when 
given intravenously.
RECENT DRUGS
1. Sorivudine
       It  is  an uracil  analogue with activity against  VZV infection. It 
requires viral thymidine kinase for phosphorylation.
2. Brivudine
        It is a new uracil derivative with potent and specific activity against 
VZV. It is effective in a single or twice daily doss orally (50-200 mg) in 
immunocompetent  adults  and  older  patients.  In  immunocompromised 
patients. It is as effective as IV acyclovir in doss of 125 mg tab every 6 
hours.
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3. Oral enzyme therapy 
        Oral enzyme therapy is beneficial in disease characterized in part by 
TGFβ over production that included shingles patients.
4. Human Interferon-A
        Interferons are synthesized by DNA recombinant technology. Its 
nonspecific  antiviral  effects,  involving synthesis  of  RNA and additive 
protein  with  immunomodulatory  effects  help  in  preventing  VZV 
synthesis and elimination of infected cells.
Role of steroids in herpes zoster management
         Combination  therapy  of  steroid  and  acyclovir  resulted  in  an 
improved quality of life, as measured by reduction in use of analegesics, 
the  time  to  uninterrupted  sleep,and  the  time  to  resumption  of  usual 
activities. However, neither study demonstrated any effect of steroids on 
the incidence or duration of post herpetic neuralgia.
Treatment of acute pain associated with herpes zoster
        For acute pain scheduled short acting narcotic analgesics should be 
prescribed. For persistent pain, long acting controlled release opioids are 
preferred.  If  pain  control  remains  inadequate,  then  regional  or  local 
anesthetic  nerve  blocks  should  be  considered.  The  effectiveness  of 
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carefully managed opiates, and tricyclic antidepressants during the acute 
phase of herpes zoster in reducing the incidence, duration and severity of 
PHN is not known. Intradermal steroids, xylocaine and epinephrine can 
also be given.
Treatment of post herpetic neuralgia
Topical therapy
        Topical lidocaine patch
        Topical EMLA cream
        Topical capsaicin (0.025%) cream
        Topical aspirin tablets in chloroform 
        Doxepin cream (5%)
Systemic treatment
1. Anticonvulsants
       For stabbing pain sodium valproate, clonazepam, carbamazepine and 
gabapentin are effective.
2. Tricyclic antidepressants
       Desipramine, nortriptyline, maprotiline amitriptyline are effective in 
post  herpetic  neuralgia.  They  are  thought  to  act  independent  of  their 
antidepressant action.
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3. Oxycodone
        Controlled release oxycodone (10mg every 12 hrs ) is an effective 
analgesic for the management of steady pain, paroxysomal spontaneous 
pain and allodynia.
4 .Analgesics
        Aspirin and other NSAIDS are commonly used in patients with post 
herpetic neuralgia but their value is limited. Tramadol a centrally acting 
analgesic  with  opioid  and  non  opioid  activities  also  effective  in  post 
herptic neuralgia(Maximum dose 600 mg / day) 
5 .Antipsychotic
        Fluphenazine, chloroprothixene and perphenazine are used with 
other drugs.
Other modalities of treatment
•   Intrathecal methyl prednisolone
•   Intradermal steroids, xylocaine and epinephrine injection.
•   Sympathetic blocks (Stellate ganglion or epidural) with 0.25%  
        Bupivacaine prevents or relieves post herpetic neuralgia.     
        Epidural injection are made at or just above the highest  
        dermatome of rash .
 
36
•    TENS(Transcutaneous electrical nerve stimulation ) may be    
        helpful,
•   Acupuncture 
•   Spinal cord stimulator
•   Biofeed back
•   Jaipur block
       This consists of local subcutaneous infiltration of 2 % lignocaine, 
0.5% bupivacaine and 4 mg per ml.dexamethasone,2.5ml each taken in a 
syringe and from which 4-5 ml of clear solution is given blindly at about 
4  -10  sites  in  one  sitting.  By  this  method,  reported  from India,28% 
reported complete relief at 6 weeks 57% after second injection and 11% 
after 3 rd injection.
Surgical procedures
1. Division of dorsal root/tracotomy.
2. Rhizotomy (Surgical separation of pain fibers)
3. Electro coagulation of well defined area of dorsal root.
4. Electrical stimulation of thalamus and spinal cord
5. Anterolateral cordotomy.
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Prevention of herpes zoster 
Zoster vaccine live (Oka/Merck)
        A subcutaneously administered live high titer (18,700 to 60,000 plaque 
forming units per dose) Varicella zoster virus vaccine of oka/Merck strain 
has been evaluated for prevention of herpes zoster and reduction of zoster 
associated pain in adults aged 60 years or above.
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AIM OF THE STUDY
A. The  Study  of  clinical  spectrum  of  Herpes  zoster  was 
undertaken to find out
     1. Age Distribution
     2. Sex Distribution
     3. Prevalence of Prodromal symptoms
     4. Prevalence of presenting complaints and 
         Constitutional symptoms
     5. Pattern of dermatomal involvement 
     6. Prevalence of Risk factors 
     7. Association with cutaneous and systemic diseases if any.
     8. Prevalence of complications
B. Therapeutic Trial
                To compare the efficacy of Famcyclovir 500 mg 3 times daily Vs 
Acyclovir 800 mg 5 times daily for 7 days of 10 cases each.
MATERIALS & METHODS
   A. Clinical Study
                 The study was conducted between August 2007 and July 2009 at  
the  department  of  dermatology,  Chengalpattu  Medical  College, 
Chengalpattu,  on  30  cases  of  herpes  zoster.  All  cases  of  herpes  zoster 
attending skin out patient department and referred cases of zoster from other 
department were studied.
                 Preliminary information including demographic data was taken  
from all patients followed by a clinical examination. This included general  
physical  examination,  complete  systemic  examination  and  thorough 
dermatological examination. A detailed history regarding the prodromal and 
presenting symptoms, day of occurrence of skin lesions, nature of pain and 
its  intensity  and duration,  and other  symptoms if  any,  were  elicited  and 
recorded. Also, history of chicken pox and previous attack of herpes zoster  
was  noted.  History  suggestive  of  provocative  factors  like  drug,  recent 
trauma, surgical manipulation of spine, irradiation, immunosuppression, and 
tumor involvement of cord and ganglion are noted.
                 Patients were screened for signs and symptoms of cutaneous, 
systemic  and  neoplastic  diseases  and  also  diabetes  mellitus,  pulmonary 
tuberculosis and exposure to the risk of sexually transmitted diseases,
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                 A thorough dermatological examination regarding the following  
features  like  segment  (s)  involvement,  morphological  pattern  of  lesions, 
presence  of  tenderness/hyperesthesia,  lymphnode  enlargement, 
dissemination of lesion in other areas of the body and other dermatological 
diseases related or unrelated to zoster.
                 Whenever necessary, opinions from ophthalmologist, neurologist,  
chest physician and general physician were sought.
                 Diagnosis  of  herpes zoster  lesion was made clinically.  
Investigations such as Tzanck Smear (in Leishman’s Stain), skin biopsy, 
complete hemogram, urine examination, blood sugar, blood VDRL, ELISA 
and radiological examinations were carried out in relevant patients.
                 All  Patients were treated with acyclovir 800 mg 5 times daily For 
7-10 days .Antibiotics, analgesics were also instituted in some of cases, with 
topical application included calamine lotion,
1% silver sulfadiazine.
                 
              
   All  the  patients  were  treated  in  the  outpatient  department  and 
subsequently  they  were  followed  depending  upon  the  cases  and 
complications  encountered,  till  the  resolution  of  signs  and  symptoms. 
Complications  like  secondary  bacterial  infection,  ulceration,  delayed 
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healing, scarring, and post herpetic neuralgia were also noted and treated 
accordingly. 
A. Therapeutic trial
                  This randomized prospective comparative study was carried out 
at chengalpattu Medical College, Chengalpattu, during the year from August 
2008  to  August  2009  on  20  herpes  zoster  patients.  The  patients  were 
assigned into two groups.
Group I
                 Includes 10 patients in whom Acyclovir 800 mg 5 times a day  
was given for 7 days
Group II
                 Includes 10 patients in which Famcyclovir 500 mg 3 times a day  
was given for 7 days
Inclusion criteria
                 The following patients were included in the study
1. Age over 18 years 
2. Patients presenting within 72 hrs of onset of lesions.
Exclusion criteria 
1. Patients with visceral involvement. 
2. Patients with motor neuropathies, encephalitis or cerebro vascular 
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complication.
3. Pregnancy or lactating females. 
4. Patients with concurrent malignancies. 
5. Patients with auto immune diseases. 
Efficacy assessment
                Patients were evaluated for pain and healing of cutaneous lesion on 
each of 7 days which receiving treatment and every other day for 7 days post 
therapy then every 7 days for at least a total of 4 months
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A.CLINICAL SPECTRUM
1. AGE SEXWISE PREVALENCE OF ZOSTER
Table -1
S.No. Age group Male Female Total no. of cases Percentage (%)
1 1- 10 0 1 1 3.3
2 11- 20 1 0 1 3.3
3 21-30 1 3 4 13.3
4 31-40 2 1 3 10.0
5 41- 50 3 2 5 16.7
6 51- 60 5 3 8 26.7
7 61- 70 3 3 6 20.0
8 71- 80 1 0 1 3.3
9 81- 90 1 0 1 3.3
Total 17 13 30
  
              Out of 30 cases, 17 cases were males and 13 were females.
Age wise distribution (Table-1) Shows that 14 cases were below the age of 50 and 
16 were above the age of 50 years.
              Maximum numbers of cases were seen between the age group of 51 to 60 
years (26.7 %) and 61 to 70 years (20%) this was followed by 41 to 50 years (16.7 
%) and 21 to 30 years (13.3 %). Minimum number of cases were observed in the 
age group of 1 to 10 years (3.3%), 71 to 80 years (3.3%). and 81 to 90 years  
(3.3%).
            The youngest was 9 years and oldest was 81 years of age, Out of 30 cases, 17 
were  males  and  13were  females  and  the  sex  ratio  is  1.30:1(male:  female) 
approximately.
2. PREVALENCE OF PRODROMAL   SYMPTOMS
The following prodromal symptoms were recorded.
1. Pain
2. Burning sensation. 
3, Constitutional symptoms (Fever, Headache)
                   
         Prodromal symptoms were present in 23 cases and absent in 7 cases. Pain prior  
to the onset of skin rash was the commonest prodromal symptom in 50%.The next  
common prodromal symptom seen was burning sensation in 13.3%. Constitutional 
symptoms (Fever, Headache) were present in 13.3%.
PREVALENCE OF PRODROMAL SYMPTOMS
Table -2
S.No. Prodromal symptoms Total no. of 
cases
Percentage (%)
1 Pain 15 50.00
2 Burning sensation 4 13.33
3 Constitutional symptoms 4 13.33
4
Absence of Prodromal 
symptoms
7 23.33
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3. PREVALENCE OF PRESENTING COMPLIANTS
    AND CONSTITUTIONAL   SYMPTOMS                         
           
              Main presenting complaint was skin rash. The other presenting complaint 
was pain. In 50 % of cases pain was present prior to the onset of skin rash and the 
remaining 33.3% of cases developed pain during evolution of skin rash.
              The constitutional symptoms presented were fever, headache, myalgia and  
joint pain.
 4.  MORPHOLOGY OF LESION AND PATTERN OF   
      DERMATOME   INVOLVEMENT  
             
              The most common dermatome affected was thoracic dermatome(40%) 
followed by an area of  ophthalmic  branch of  trigeminal  nerve  in  10% of cases, 
cervical in 10% of the cases and lumbar segment in 7% of the cases.              
              Thoracolumbar and cervicothroraic involvement was 6.67% and3.3% 
respectively. The least common dermatome involved was sacral dermatome (3.3%).
               The pattern of dermatome involvement was almost similar in both sexes.  
97% of patient presented with grouped vesicles on an erythematous background in  
dermatomal  distribution.  The  remaining  3%  of  cases  presented  with  erosions, 
crusting and pustules.
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PATTERN OF   DERMATOME INVOLVEMENT
Table - 3
S.No. Dermatome Sex Side No. of 
cases
Percentage
(%)Male Female Left Right
1 Thoracic 10 2 6 6 12 40.00
2 Lumbar 1 1 1 1 2 6.67
3 Cervical 2 1 1 2 3 10.00
4 Sacral 0 1 1 0 1 3.33
5 Thoraco 
Lumbar
2 0 1 1 2 6.67
6 Cervico 
thoracic
1 0 0 1 1 3.33
7 Opthalmic 2 1 2 1 3 10.00
8 Maxillary 1 1 1 1 2 6.67
9 Mandibular 1 1 2 0 2 6.67
10 Herpes zoster 
oticus
1 1 2 0 2 6.67
Total 21 9 17 13 30
5. MULTIDERMATOMAL INVOLVEMENT AND DISSEMINATION
            Multidermatomal involvement was noted in a female case (45 years) of  
herpes zoster with HIV positive. She had involvement of cervical dermatome C2 to  
C5 segments.
 No recurrence of Herpes zoster was observed in any case.
6. LYMPH NODE ENLARGEMENT
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          Regional lymph node enlargement was noted in 95% of cases. Nodes were 
tender in 80% of cases and non tender in 15 % of cases and are firm in consistency. 
7. PREVALENCE OF RISK FACTORS
            Out of 30 cases, 8 cases were having one or more suspected risk factors.  
Among the 8 cases 2 were having HIV(25%), 3 were having diabetes (50%)and 3 
were on steroid therapy for various other problems(25%).
PREVALENCE OF RISK FACTORS
Table -4
S.No. Provocative 
Factors
Male Female Total no. of 
cases
Percentage
(%)
1 HIV 1 1 2 25
2 Diabetes 3 1 4 50
3 Steroid therapy 1 1 2 25
Total 5 3 8
 
8. PAST HISTORY OF CHICKEN POX
            Out of 30 cases, 90 % gave definite history of of chicken pox. 10 % of 
patient did not give any history of chicken pox. Of these 90%of patients, 33 % of 
cases  gave history of chicken pox between 11 to 20 years of age and   30% of cases 
gave history of varicella between 1 to 10 years of age. 
49
AGE GROUP WISE PAST HISTORY OF CHICKEN POX
Table -5
S.No. Age group Male Female Total Percentage (%)
1 1-10 Years of age 6 3 9 30.0
2 11-20 Years of age 6 4 10 33.0
3 H/O Chicken pox in 
childhood (exact 
age is not Known)
5 3 8 27.0
4 No History of 
chicken pox
2 1 3 10.0
 Total 19 11 30
        
9. ASSOCIATED CUTANEOUS AND SYSTEMIC 
    DISEASES      
            Cutaneous diseases seen in association with herpes zoster were acne 1 case. 
Seborrhoeic dermatitis two cases, tinea vesicular 2 cases, Hansen’s disease  1 case,  
insect bite allergy 2 cases ,wart 1 caser ,cellulites 1 case ,oral candidiasis 1 case 
,tinea cruris 1 case and intertrigo 1 case.
            The associated systemic diseases were hypertension (2 cases), bronchial  
asthma (2 cases) and tuberculosis (I case). 
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10. INVESTIGATIONS
            Complete hemogram was within normal limits except for increased ESR in 2  
patients, increased neutrophil count in 1 patient, and decreased hemoglobin value in 
4 patients.
            Blood sugar was elevated above the normal value in 7 patients. Urine routine 
examination  was  normal  in  almost  all  patients  (98%).Urine  examination  showed 
reducing sugar in 2 patients with elevated blood glucose value.
              ELISA test for HIV was done in all patients .Positive ELISA test result was  
obtained in 2 patients .One patient already diagnosed as HIV positive and presented 
with zoster during the course of HIV disease.
            ECG was taken for patients with zoster involving left thoracic segment and it  
was found to be normal. Diabetologist opinion for 4 patients, neurologist opinion for 
1patient, ophthalmologist opinion for 2 patients.
            Tzanck smear showed multinucleated giant cells and ballooned epithelial 
cells in 95% of cases. Skin biopsy was done in willing patients which under light 
microscope  in  eosin  and  haematoxylin(H&E)  staining  showed  intraepidermal 
uniloculated  to  multiloculated  bullae  with  ballooned  epithelial  cells  and 
multinucleated giant  cells.  Reticular  degeneration seen in some areas.  The upper 
dermis showed inflammatory infiltrate composed of lymphocytes, monocytes and 
few eosinophils. 
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11. COMPLICATIONS 
a. Secondary bacterial infection
            Secondary bacterial infection was reported in 4 cases (36.36%). In 2% of 
patients affected with secondary infection scarring occurred in affected dermatome. 
Cases were treated with topical Silver sulphadiazine cream and systemic antibiotics 
in addition to acyclovir.
b. Scarring
            Scarring was noted in 2 cases (18.8%),  which were associated with 
secondary bacterial infections and later developed ulceration.
       C. Post herpetic neuralgia
            PHN is the most feared complication in immunocompetent patients. Both the 
incidence and duration of post herpetic neuralgia are directly correlated with the 
patient’s  age.  Out  of  11  patients  with  complications  of  zoster,5  cases  (45.5%) 
developed post herpetic neuralgia.
            Among the 5 cases of post herpetic neuralgia,3 were males and 2 were  
females. 
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PREVALENCE OF COMPLICATIONS
Table-6
S.No. Complications Male Female Total Percentage
(%)
1 Scarring 2 0 2 18.18
2 Secondary 
bacterial 
infection
3 1 4 36.36
3 Post herpetic 
neuralgia
3 2 5 45.45
TOTAL 8 3 11
B.THERUPETIC TRIAL
1. TIME TAKEN FOR RESOLUTION OF LESIONS
Table-1
Patients 
S.No.
DRUG
ACYCLOVIR FAMCYCLOVIR
Duration in days Duration in days
1 12 11
2 14 12
3 - 11
4 14 14
5 12 -
6 22 12
7 11 15
8 14 17
9 18 13
10 - 10
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Medium  time  for  resolution  of  lesion  was  14.6  days  in  acyclovir  group  and 
12.8  days  in  famcyclovir  group.  The  difference  in  time  taken  for  resolution  of  
lesions between acyclovir and famcyclovir was not significant (P=0.78) 
2. INCIDENCE OF POSTHERPETIC NEURALGIA
Table-2
Patients 
S.No.
POSTHERPETIC NEURALGIA
ACYCLOVIR FAMCYCLOVIR
1 Present Absent
2 Absent Absent
3 Absent Absent
4 Absent Present
5 Absent Absent
6 Present Absent
7 Absent Absent
8 Absent Absent
9 Present Absent
10 Absent Absent
Post herpetic neuralgia was present in 30 % of the cases with Acyclovir group and 
10% of the cases with famcyclovir.
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DISCUSSION
A. Clinical Spectrum  
       Herpes zoster is common among immunocompromised persons, so the elderly 
are at particular risk because immunocompetence declines with age. Whitley et al51 
reported  that  zoster  affects  20%  of  general  population  during  their  life  time, 
especially in elderly. This study of 30 patients with herpes zoster revealed that the 
majority of the patients affected were adults in the fifties (26.7), and sixties (20 
%).This is in accordance to the observation made earlier in other studies 25 where in 
most cases are in the age group above 50 years with highest  incidence among 
individuals in the sixth to eighth decades of life.
       Total number of cases in childhood and adolescence age group were 3 in  
number.
       In this study male: female ratio was 1.3:1 which is in accordance to the  
western studies 52 ,where both males and females were equally affected.    
       Prodromal symptoms were in 23 cases (76%) in this study .In majority of  
cases, pain was the commonest prodromal symptom.       
       In this study, majority of the cases (74%) presented between 2 to 5 days and 
the remaining 26% of cases presented between 6 to 8 days and above, which is 
similar to the study report given in western literature25.
           Most common presenting symptom in this study was pain and skin rash was 
the next common presenting complaint which is similar to various study reports25, 
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       Constitutional symptoms were noted in 75% of cases in this study.
       In this study, 97% of cases had classical herpes zoster in dermatomal pattern 25 
and 3% of cases had crusting and erosions. 
       Thoracic dermatome was the most common dermatome involved (40%) in this  
study, followed by cervical and ophthalmic dermatome in 10% of cases each and 
lumbar dermatome in 6.7% of cases, in accordance with the literature reports  33. 
The least common dermatome involved was sacral segment.
       Out of 30 cases,  97% of cases had localized involvement with grouped  
vesicles and 1% of cases had multi  dermatomal involvement.  Multidermatomal 
zoster was seen in a case with underlying immunodeficiency (HIV infection). 
       Eight cases were having one or more suspected risk factors. Out of  8 cases,  
most common risk factors seen was diabetes in 4 cases (50%),HIV infection in 2 
cases ( 25%)  and 2 cases (25%) on steroid therapy.
       Past history of chicken pox was given by 90% of cases. The remaining 10% of  
cases were either not aware of or not had chicken pox.
       Systemic disease seen in association with herpes zoster was hypertension 2 
cases, bronchial asthma 2cases, and tuberculosis 1case.
       Few cutaneous disease seen in herpes zoster patients in this study were acne,  
tineaversicolor, seborrheicdermatitis insectbiteallergy, Hansen’s disease, cellulitis, 
oralcandidiosis, tineacruris and intertrigo, one case each.
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       Tzanck smear was positive in 95% of cases and it was negative in 5% of cases 
and this correlates well with that of literature reports25 .Complete hemogram was 
normal in 80% of cases in this study. This is in contrast to the literature reports, 
where in normal complete hemogram are reported in zoster patients.Raised ESR 
was noted in 2 patients and decreased hemoglobin value was noted in 4 patients. 
       Blood sugar was elevated in above normal value in 4 patients.Urine routine 
examination was normal in almost all patients (98%).Urine examination showed 
reducing sugar in 2 patients (6.6%).
       In this study, 2 cases out of the 30 patients who were tested for HIV were sero  
positive. Among the 2 cases of HIV positivity, herpes zoster was the presenting 
disease for HIV infection in 1  case. Recurrence of zoster in HIV positive patients 
were not observed in this study.
       Skin biopsy showed histopathological features as described in 
literature 25/11.
       ECG was taken for  all  cases  with lesions involving left  upper  thoracic 
dermatomes and no abnormality was detected.
       Post herpetic neuralgia was the commonest complications noted in 5 patients 
(45.45%) followed by secondarybacterialinfection in 4cases (36.36%), scarring in 
2 cases (18.8%) .
       In accordance to the literature reports, the incidence of post herpetic neuralgia  
increased with increasing age in this study.
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 Therapeutic trial
• In Total, 20 patients were enrolled in the study and divided 
     into two groups.
• In Group I: 10 patients were given Tab Acyclovir 800 mg 
     5 times/day for 7 days.
• In Group II: 10 patients were given Tab Famcyclovir500mg
     3 times/day for 7 days. 
• Out of 10 patients in Group I: 2 patients did not complete 
      the study. The reason was due to 
(i) Deviation from protocol.
(ii) Loss of follow up.
• Out of 10 patients in group II: 1 patient did not complete 
      the study. The reason was due to loss of follow up.
• In this study, median time for resolution of lesions was 14.6 days 
     in group I and 12.8 days in Group II, this is inaccordance
     with literature report55.
• During treatment,  5  patients  in  group I  had  adverse effects  such as  constipation,  dysuria,  headache, 
nausea and 2 patients in group II had side effects such as head ache and nausea. The frequency of adverse 
effects was low in group II compared to group I.
• The incidence of PHN in group I was 30%.and group II was 10%, this is inaccordance with literature  
report55.
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Conclusion
• In this study, herpes zoster mainly occurred in fifth and sixth decades 
of life.
• No sex  preponderance  in incidence was found with the sex ratio of 
1.3:1
• Prodromal symptoms were present in 76 % of cases and pain was the 
commonest prodromal symptom.
• Most common presenting symptom was pain followed by skin rash.
• Thoracic dermatome was the most common dermatome involved and 
sacral segment was the least common dermatome affected.
• The  risk  factors  noted  were  diabetes,  HIV  infection  and  steroid 
therapy.
• HIV infection was present  in 2 cases.  Out of 2 cases,  1 case was 
already  diagnosed  as  HIV  positive  and  developed  herpes  zoster 
during the course of HIV disease. This indicates the importance of 
HIV testing in all patients presenting with herpes zoster, especially in 
patients below age of 50 years.
• The  systemic  diseases  associated  with  herpes  zoster  were 
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hypertension, bronchial asthma and tuberculosis.
• No significant association of herpes zoster was found with any  other 
skin disorder in this study.
• Duration of time taken for resolution of lesions, ranged from  2  to 3 
weeks.
• Post herpetic neuralgia was noted in patients with increasing age. 
Therapeutic Trial 
         This study indicates that  Famcyclovir  is  more effective than 
Acyclovir interms of parameters such as incidence and duration of post 
herpetic neuralgia, patient’s compliance and adverse effects. However, 
there was no statistical significant difference in the duration of resolution 
of lesions between acyclovir and famcyclovir treated patients (P=0.78)
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PROFORMA
S.No:                                                                            OP/IP No:
Name:                                      Age                              Sex  
Occupation:                                                                Address:
PRESENTING COMPLAINTS:
             H/O PRESENTING ILLNESS
1. H/o. Pain   Onset- Prehepetic/Herpetic
Nature-Burning/Tingling/Deep boring/Lancinating  
2. H/o cutaneous lesions: Papules/Vesicles/Grouped /Diffuse 
3. H/o Paraesthesia
4. H/oConstitutional Symptoms: Fever, Malaise, Headache.
5. H/o Itching, tingling, numbness over the involved site.
6. H/o Difficulty in swallowing.
7. H/o Pain &Photophobia in eye.
8. H/o Watering in eye.
9. H/o Toothache (Oral facial Zoster)
10. H/o Otalgia
11. H/o Difficulty in urination /defaecation
12. H/o Precipitating Factors/predisposing Factors- Stress, Trauma, 
Radiation,               
      Recent surgery, organ transplantation,   
      Systemic conditions: DM/Malignancy 
      
           PAST HISTORY
       H/o Varicella
       H/o Contact with Chickenpox/Herpes Zoster.
       H/o Diabetes/ TB/ HT
       H/o Recurrent Zoster
            TREATMENT HISTORY 
        H/o Treatment for Malignancy
        H/o Steroid Therapy /other immunosuppressive drug therapy
        H/o Treatment for HIV
        H/o Treatment for Diabetes.
        H/o Radiotherapy
FAMILY HISTORY
 H/o Varicella in any other family members (for contact exacerbation).
PERSONAL HISTORY
        H/o Alcoholism/Smoking
MENTURAL HISTORY
SEXUAL HISTORY
         Hetero/homo/Bisexual                          Protected/unprotected
         Known/unknown partner                            
         Single/Multiple partner                               
      GENERAL EXAMINATION
         Built&Nourishment
              Pallor, Icterus, Edema, Lymphadenopathy (Regional/Generalized)
              Eyes, 
                Vitals: Febrile/Afebrile.
SYSTEMIC EXAMINATION
              CVS:                                                                  RS:
             ABD:                                                               CNS:
DERMATOLOGICAL EXAMINATION
1. Site of the lesion         -  Dermatome involved       
                              
2. Morphology                - Erythema/ Papules/ vesicles/ Crust/ Erosion   
3.  Pattern              - Grouped / Localised/Dissminated/Multidermatome 
3. Sensory involvement-   Tenderness/Hyperesthesia
4. Motor involvement   -    Cranial nerves/Trunks/Limbs  
5. Mucous Membrane   -   Eyes/Oral Mucosa/Genital Mucosa    
6. Nails and Hairs
7. Palms and Soles
8. Complications:  
      Cutaneous -      Secondary infection/ulceration
                                     Scarring- Atrophic/Hypertrophic/Keloidal Anesthetic/
                                     Pigmented /Depigmented 
                                     Phantom hernia
            Eye complication
            Neurological complication: Post herpetic neuralgia/others 
           Visceral complication: Respiratory Tract/GIT/GUT
        
       INVESTIGATIONS
1. Blood                                TC, DC, and ESR, Hb%
2. Urine                                 albumin, Sugar, Deposit
3. Blood                                Sugar, Urea
4. Serum                                creatinine
5. Tzanksmear                       
6. Blood VDRL                     
7. ELISA                                
8. Skin Biopsy (If necessary) 
9. ECG (If necessary)             
10.CXR PA view                      
11.USG abd(Selected Case)     
TREATMENT
Symptomatic Treatment
Antiviral Treatment   
    A. T.Acyclovir 800 mg 5 times a day for    1 week
    B.T.Famcyclovir 500 mg 3 times a day for   1week
Follow up; (for 4 months)
               Variables                                        Acyclovir            Famcyclovir
• Time taken for resolution of lesions 
• Incidence of post herpetic neuralgia.
• Adverse effects
Acronyms 
l.No Acronyms Expansion
1 PHN Post Herpetic Neuralgia
2 HIV Human Immuno Deficiency Virus Infection
3 FCV Famcyclovir
4 ACV Acyclovir
5 Carbamaz Carbamazepine
6 ESR Erythrocyte sedimentation Rate
7 ELISA Enzyme Linked Immuno Sorbent Assay
8 RFT Renal Function Test 
9 ECG Electro Cardiogram
10 CRF Chronic Renal Failure
11 HT Hypertension 
12 Hb Hemoglobin
13 IBA Insect Bite Allergy
14 TB Tuberculosis
15 Rt Right
16 Lt Left
17 TV Tinea versicolor
18 VZV Varicella Zoster Virus
